In-silico design and study of novel piperazinyl β-carbolines as inhibitor of HIV-1 reverse transcriptase

Medicinal Chemistry Research

Volumn 24, Issue 2, 2015, Pages 513-522

  Ashok, Penta ^a   Sharma, Hardik ^a   Lathiya, Hiren ^a   Chander, Subhash ^a   Murugesan, Sankaranarayanan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Acquired immune deficiency syndrome (AIDS); Docking; HIV 1 reverse transcriptase inhibitors; NNRTIs; Carboline

Indexed keywords

EID: 84939885330     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-014-1141-7     Document Type: Article

References (15)

1. Bethune M (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 85:75-90
2. Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, Lee P, Tang Y (2012) admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 52:3099-3105
3. De Clercq E (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38:153-179
4. Garrett M, Ruth H, William L, Michel S, Richard B, David G, Arthur O (2009) Autodock4 and autodocktools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785-2791
5. Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye NA, Mboup S, Kanki PJ (2003) Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 22:573-593
6. Hedley P, Jorgensen P, Schlamowitz S, Wangari R (2009) The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 30:1486-1511
7. Leigh AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ (2003) Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187:683-686
8. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26
9. Maga G, Spadari S (2002) Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. Curr Drug Metab 3:73-95
10. Ragno R, Artico M, Martino G, Regina G, Coluccia A, Pasquali A, Silvestri R (2005) Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl) carbohydrazide derivatives. J Med Chem 48:213-223
11. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401
12. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463-469
13. Schüttelkopf AW, Van Aalten DMF (2004) PRODRG - a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr 60:1355-1363
14. Valdez RH, Tonin LTD, Nakamura TU, Filho BPD, Diaz JAM, Sarragiotto MH, Nakamura CV (2009) Biological activity of 1,2,3,4-tetrahydro-b-carboline-3-carboxamides against Trypanosoma cruzi. Acta Trop 110:7-14
15. Umamaheswari M, Aji CS, Asokkumar K, Sivashanmugam T, Subhadradevi V, Jagannath P, Madeswaran A (2012) Docking studies: In silico aldose reductase inhibitory activity of commercially available flavonoids. Bangladesh J Pharmacol 7:108-113